Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 14, 2013, Pages 4679-4689

  Bergamaschi, Mateus M ^a,b   Barnes, Allan ^a   Queiroz, Regina H C ^b   Hurd, Yasmin L ^c   Huestis, Marilyn A ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Biomedical Research Center   (United States)

Author keywords

Cannabidiol; Cannabidiol glucuronide; Enzymatic hydrolysis; GC MS; Urine

Indexed keywords

BODY FLUIDS; EXTRACTION; PHARMACOKINETICS; PHASE SEPARATION; PLANT EXTRACTS; SULFUR COMPOUNDS;

CANNABIDIOL; EXTRACTION EFFICIENCIES; GC-MS; GLUCURONIDES; LINEAR LEAST SQUARES; SOLID-PHASE EXTRACTION; THERAPEUTIC APPLICATION; URINE;

ENZYMATIC HYDROLYSIS;

ALKALI; BETA GLUCURONIDASE; CANNABIDIOL;

ARTICLE; CHEMISTRY; HUMAN; HYDROLYSIS; MASS FRAGMENTOGRAPHY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; URINE; PROCEDURES;

ALKALIES; CANNABIDIOL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDASE; HUMANS; HYDROLYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84891721825     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-013-6837-x     Document Type: Article

References (44)

1. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515-527
2. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, Martin-Santos R, Hallak JE, Zuardi AW, Crippa JA (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219-1226
3. Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30:271-280
4. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237-249
5. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216-221
6. Morgan CJ, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306-307
7. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol (Berl) 76:245-250
8. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488-491
9. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66:175-181
10. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172-177
11. Zuardi AW, Hallak JEC, Crippa JAS (2012) Interaction between cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 219:247-249
12. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011) Plasma cannabinoid pharmacokinetics following controlled oral delta9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57:66-75
13. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, Huestis MA (2011) Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89:400-407
14. Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121:35-43
15. Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168:657-690
16. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K (2011) Identification of cytochrome P450 enzymes responsible for metabolismof cannabidiol by human livermicrosomes. Life Sci 89:165-170
17. Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) The pharmacology of marihuana. Raven, New York, pp 93-113
18. Paton WD, Pertwee RG (1972) Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol 44:250-261
19. Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303-320
20. Harvey DJ, Martin BR, Paton WD (1976) Identification of the glucuronides of cannabidiol and hydroxycannabidiols in mouse liver. Biochem Pharmacol 25:2217-2219
21. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH (2009) Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37:1496-1504
22. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995) Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19:285-291
23. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ (1995) Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19:292-298
24. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA (2007) Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9- tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 31:477-485
25. Grauwiler SB, Scholer A, Drewe J (2007) Development of a LC/ MS/MS method for the analysis of cannabinoids in human EDTAplasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Analyt Technol Biomed Life Sci 850:515-522
26. Scheidweiler KB, Desrosiers NA, Huestis MA (2012) Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta 413:1839-1847
27. GOMA Biotec (2011) GOMA Biotec Product Information Sheet-b-Glucuronidase from Haliotis rufescens (abalone). Product Information: 1-2
28. Sigma-Aldrich (2005) Sigma Product Information Sheet-b-Glucuronidase Type IX-A from Escherichia coli. Product Information: 1-2
29. Sigma-Aldrich (2008) Sigma Product Information Sheet-b-Glucuronidase Type HP-2 from Helix pomatia. Product Information: 1-2
30. Zanchetti G, Floris I, Piccinotti A, Tameni S, Polettini A (2012) Rapid and robust confirmation and quantification of 11-nor-Delta9- tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in urine by column switching LC-MS-MS analysis. J Mass Spectrom 47:124-130
31. Fernandez Mdel M, Wille SM, Samyn N, Wood M, Lopez-Rivadulla M, De Boeck G (2009) On-line solid-phase extraction combined with liquid chromatography-tandem mass spectrometry for high throughput analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in urine. J Chromatogr B Analyt Technol Biomed Life Sci 877:2153-2157
32. Paul BD, Mell LD Jr, Mitchell JM, McKinley RM, Irving J (1987) Detection and quantitation of urinary 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of tetrahydrocannabinol by capillary gas chromatography and electron impact mass fragmentography. J Anal Toxicol 11:1-5
33. Robandt PV, Klette KL, Sibum M (2009) Automated solid-phase extraction-liquid chromatography-tandem mass spectrometry analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human urine specimens: application to a high-throughput urine analysis laboratory. J Anal Toxicol 33:456-460
34. Thomas BF, Compton DR, Martin BR (1990) Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 255:624-630
35. Garrett ER, Hunt CA (1974) Physiochemical properties, solubility, and protein binding of delta-9-tetrahydrocannabinol. J Pharm Sci 63:1056-1064
36. Johnson JR, Jennison TA, Peat MA, Foltz RL (1984) Stability of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 8:202-204
37. Fairbairn JW, Liebmann JA, Rowan MG (1976) The stability of cannabis and its preparations on storage. J Pharm Pharmacol 28:1-7
38. Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharmaceutica Suecica 8:391-402
39. Gray T, Barnes A, Huestis M (2010) Effect of hydrolysis on identifying prenatal cannabis exposure. Anal Bioanal Chem 397:2335-2347
40. Harvey DJ, Samara E, Mechoulam R (1991) Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 40:523-532
41. Harvey DJ, Samara E, Mechoulam R (1991) Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr 562:299-322
42. Karschner EL, Barnes AJ, Lowe RH, Scheidweiler KB, Huestis MA (2010) Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem 397:603-611
43. Gaoni Y, Mechoulam R (1966) Hashish VII: the isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 22:1481-1488
44. Adams R, Pease DC, Cain CK, Clark JH (1940) Structure of cannabidiol. VI. Isornerization of cannabidiol to tetrahydrocannabinol, a physiologically active product. Conversion of cannabidiol to cannabinol. J Am Chem Soc 62:2402-2405